Author Correction: Discovery of a selective catalytic p300/CBP inhibitor that targets lineage-specific tumours

Loren M Lasko; Clarissa G Jakob; Rohinton P Edalji; Wei Qiu; Debra Montgomery; Enrico L Digiammarino; T Matt Hansen; Roberto M Risi; Robin Frey; Vlasios Manaves; Bailin Shaw; Mikkel Algire; Paul Hessler; Lloyd T Lam; Tamar Uziel; Emily Faivre; Debra Ferguson; Fritz G Buchanan; Ruth L Martin; Maricel Torrent; Gary G Chiang; Kannan Karukurichi; J William Langston; Brian T Weinert; Chunaram Choudhary; Peter de Vries; Arthur F Kluge; Michael A Patane; John H Van Drie; Ce Wang; David McElligott; Edward A Kesicki; Ronen Marmorstein; Chaohong Sun; Philip A Cole; Saul H Rosenberg; Michael R Michaelides; Albert Lai; Kenneth D Bromberg

doi:10.1038/s41586-018-0111-5

Author Correction: Discovery of a selective catalytic p300/CBP inhibitor that targets lineage-specific tumours

Nature. 2018 Jun;558(7710):E1. doi: 10.1038/s41586-018-0111-5.

Authors

Loren M Lasko¹, Clarissa G Jakob¹, Rohinton P Edalji¹, Wei Qiu¹, Debra Montgomery¹, Enrico L Digiammarino¹, T Matt Hansen¹, Roberto M Risi¹, Robin Frey¹, Vlasios Manaves¹, Bailin Shaw¹, Mikkel Algire¹, Paul Hessler¹, Lloyd T Lam¹, Tamar Uziel¹, Emily Faivre¹, Debra Ferguson¹, Fritz G Buchanan¹, Ruth L Martin¹, Maricel Torrent¹, Gary G Chiang^{1

2}, Kannan Karukurichi³, J William Langston⁴, Brian T Weinert⁵, Chunaram Choudhary⁵, Peter de Vries⁶, Arthur F Kluge⁷, Michael A Patane⁸, John H Van Drie⁹, Ce Wang¹⁰, David McElligott¹¹, Edward A Kesicki³, Ronen Marmorstein¹², Chaohong Sun¹, Philip A Cole¹³, Saul H Rosenberg¹, Michael R Michaelides¹, Albert Lai¹, Kenneth D Bromberg¹⁴

Affiliations

¹ Discovery, Global Pharmaceutical Research and Development, North Chicago, IL, USA.
² eFFECTOR Therapeutics, San Diego, CA, USA.
³ Petra Pharma Corporation, New York, NY, USA.
⁴ Faraday Pharmaceuticals, Seattle, WA, USA.
⁵ Department of Proteomics, the Novo Nordisk Foundation Center for Protein Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
⁶ Cascadian Therapeutics, Inc., Seattle, WA, USA.
⁷ I-to-D, Inc., Lincoln, MA, USA.
⁸ Mitobridge, Inc., Cambridge, MA, USA.
⁹ Van Drie Research, Andover, MA, USA.
¹⁰ China Novartis Institutes for BioMedical Research, Zhangjiang Hi-Tech Park, Shanghai, China.
¹¹ Accelerator Corporation, New York, NY, USA.
¹² Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
¹³ Johns Hopkins University, Baltimore, MA, USA.
¹⁴ Discovery, Global Pharmaceutical Research and Development, North Chicago, IL, USA. [email protected].

PMID: 29769713
DOI: 10.1038/s41586-018-0111-5

Abstract

In the originally published version of this Letter, the authors Arthur F. Kluge, Michael A. Patane and Ce Wang were inadvertently omitted from the author list. Their affiliations are: I-to-D, Inc., PO Box 6177, Lincoln, Massachusetts 01773, USA (A.F.K.); Mitobridge, Inc. 1030 Massachusetts Avenue, Cambridge, Massachusetts 02139, USA (M.A.P.); and China Novartis Institutes for BioMedical Research, No. 4218 Jinke Road, Zhangjiang Hi-Tech Park, Pudong District, Shanghai 201203, China (C.W.). These authors contributed to the interpretation of results and design of compounds. In addition, author 'Edward A. Kesicki' was misspelled as 'Ed Kesicki'. These errors have been corrected online.

Publication types

Published Erratum

Grants and funding

R01 GM060293/GM/NIGMS NIH HHS/United States